MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Core Insights - MetaVia Inc. announced positive results from its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog for obesity treatment, showing significant weight loss and metabolic improvements [1][3][6] Group 1: Clinical Trial Results - In the non-titrated 48 mg cohort, patients achieved a statistically significant average weight reduction of 9.1% (21.2 lbs) and a waist circumference reduction of 9.8 cm (3.8 inches) by Day 54 [2][3] - The trial demonstrated a 12.3 mg/dL reduction in fasted glucose levels, indicating strong glycemic response [1][3] - A 23.7% reduction in liver stiffness was observed, suggesting a significant direct hepatic effect from DA-1726 [1][2] Group 2: Safety and Tolerability - No treatment-related discontinuations were reported, and gastrointestinal events were mild to moderate in severity [2][3] - The favorable safety profile supports the potential for DA-1726 as a best-in-class treatment option [3][4] Group 3: Future Development Plans - MetaVia plans to conduct 16-week titration studies to further evaluate DA-1726's tolerability and efficacy, with results expected in Q4 2026 [3][4] - The company aims to leverage the competitive advantage of DA-1726's dosing regimen compared to existing GLP-1 drugs [3][4] Group 4: Mechanism of Action - DA-1726 functions as a dual agonist of GLP-1 and glucagon receptors, leading to weight loss through appetite reduction and increased energy expenditure [6][7] - Pre-clinical studies indicate that DA-1726 may provide superior weight loss compared to other treatments like semaglutide and tirzepatide [6][7]